Page 1

NOVACYT GROUP Novacyt S.A. ( " Novacyt " , the " Company " or the " Group " ) Half Year Update Investor meeting at 13:00 BST / 14:00 CEST - 18 August 2021 - Novacyt ( EURONEXT GROWTH : Paris , France and Camberley , UK ALNOV ; AIM : NCYT ) , an international specialist in clinical diagnostics , announces a half year update in advance of its investor meeting today . Six months revenue ended 30 June 2021 £ ' 000 H1 2021 H1 2020 YoY Growth YoY Growth Actual % Total Group Revenue 94,710 63,252 31,458 50 % DHSC Revenue 40,759 18,406 22,353 121 % Non - DHSC Revenue 53,951 44,846 9,105 20 % Unaudited revenue for the first half of 2021 increased over 50 % to £ 94.7 million , compared to £ 63.3 million for the first half of 2020. Of this total revenue , £ 54 million came from a mixture of overseas sales and a growing UK private testing market , leading to non- DHSC revenue growing 20 % year - on - year . As announced on 21 May 2021 , the DHSC sales of £ 40.8 million are in dispute . Business update Contract award with DHSC under PHE framework Primerdesign , a wholly owned subsidiary of Novacyt , has been awarded a new contract under the PHE National Microbiology Framework , effective immediately , for the supply of PROmate® COVID - 19 tests to the NHS . The PROmate ® COVID - 19 tests have been developed to run on the Company's q16 and q32 PCR instrument platforms . The q16 and q32 near patient PCR instrument platforms using the PROmate® COVID - 19 test have been validated and can be used at select NHS hospitals . The contract is valued at up to £ 4.7m and will last until 31 March 2022. There are no minimum purchase levels as part of this contract . Separately , there is no further update to the announcement on 22 June 2021 in relation to the Company's second supply contract with the DHSC which is in dispute . Non - governmental organisation long - term agreements